Identification of molecular mechanisms for cellular drug resistance by combining drug activity and gene expression profiles

L Rickardson¹, M Fryknäs², S Dhar¹, H Lövborg¹, J Gullbo¹, M Rydåker², P Nygren³, MG Gustafsson²,⁴, R Larsson⁵,¹ and A Isaksson²

¹Department of Medical Sciences, Division of Clinical Pharmacology, Uppsala University Hospital, S-751 85 Uppsala, Sweden; ²Department of Genetics and Pathology, Uppsala University, S-751 85 Uppsala, Sweden; ³Department of Oncology, Radiology and Clinical Immunology, Uppsala University, S-751 85 Uppsala, Sweden; ⁴Department of Engineering Sciences, Uppsala University, S-751 85 Uppsala, Sweden

Acquired drug resistance is a major problem in cancer treatment. To explore the genes involved in chemosensitivity and resistance, 10 human tumour cell lines, including parental cells and resistant subtypes selected for resistance against doxorubicin, melphalan, teniposide and vincristine, were profiled for mRNA expression of 7400 genes using cDNA microarray technology. The drug activity of 66 cancer agents was evaluated on the cell lines, and correlations between drug activity and gene expression were calculated and ranked. Hierarchical clustering of drugs based on their drug–gene correlations yielded clusters of drugs with similar mechanism of action. Genes correlated with drug sensitivity and resistance were imported into the PathwayAssist software to identify putative molecular pathways involved. A substantial number of both proapoptotic and antiapoptotic genes such as signal transducer and activator of transcription 1, mitogen-activated protein kinase 1 and focal adhesion kinase were found to be associated to drug resistance, whereas genes linked to cell cycle control and proliferation, such as cell division cycle 25A and signal transducer of activator of transcription 5A, were associated to general drug sensitivity. The results indicate that combined information from drug activity and gene expression in a resistance-based cell line panel may provide new knowledge of the genes involved in anticancer drug resistance and become a useful tool in drug development.

British Journal of Cancer (2005) 93, 483–492. doi:10.1038/sj.bjc.6602699 www.bjcancer.com
Published online 12 July 2005
© 2005 Cancer Research UK

Keywords: chemotherapy; drug resistance; gene microarray

Chemotherapy is an important modality for the treatment of malignant tumours. However, for the majority of cancer patients, treatment with established anticancer drugs produces dissatisfactory long-term effects and drug activity is highly variable both between and within different diagnoses (Nygren, 2001). Genes affecting chemosensitivity are involved in drug transport, drug metabolism, DNA synthesis and repair, cell survival and apoptosis (Marie, 2001; Pommier et al, 2004). Since many different signalling pathways are involved, there is an urgent need for high-efficacy drugs with novel mechanisms of action targeting the key genes.

Rapid cell-based methods for high-throughput and focused screening based on drug-response analysis in a panel of cell lines have proven to be important tools in anticancer drug discovery and early evaluation (Paull et al, 1989; Boyd and Paull, 1995; Dhar et al, 1996; Weinstein et al, 1997). Research performed at the National Cancer Institute (NCI) has shown that a drug activity profile acquired from a nonclonogenic growth inhibition assay on a panel of 60 parental human cancer cell lines can provide important information on the mechanism of action of various compounds. Robust and accurate mechanistic drug–drug relationships have repeatedly been demonstrated using both simple correlation analysis and more sophisticated data analytical methods (Paull et al, 1989; Weinstein et al, 1992, 1997; Boyd and Paull, 1995). We have previously shown that, by applying similar techniques, a smaller panel of 10 cell lines representing different drug-resistant phenotypes could accomplish accurate classifications of mechanisms of action for common anticancer drugs (Dhar et al, 1996).

The development of novel molecular technologies such as cDNA microarrays has made it possible to identify genes involved in chemosensitivity. Integration of gene expression and drug activity data sets for cancer cells can identify relationships between individual genes and sensitivity or resistance to specific drugs. Investigators at NCI analysed the gene expression profiles of the NCI human tumour cell line panel and correlated the gene expression to growth-inhibitory activity of anticancer compounds (Scherf et al, 2000).

Several genes were identified which could be considered as candidate targets or biomarkers for chemosensitivity. The approach was considered feasible and useful for exploring the mechanisms of action, and was supported by investigators applying a similar methodology on a 39-cell line panel (Dan et al, 2002). The cell lines used in these studies consisted of parental cells of different cancer types and did not include any selected resistant phenotypes. With the aim of identifying chemosensitivity genes, the inclusion of resistant cell lines may be advantageous by increasing the range of expression in the measured microarray data, specifically for the genes involved in
development of resistance. Therefore, in the present study, a cell line panel representing different drug resistance phenotypes, rather than histological origin, was characterised with respect to gene expression and anticancer drug response, and the relationships between the resulting drug and gene expression profiles were subsequently explored. By association analyses using pathway mining software, molecular pathways putatively involved in drug resistance and sensitivity were identified.

MATERIALS AND METHODS

Cell culture
The human cancer cell line panel has been described previously (Dhar et al., 1996). The panel consists of the parental cell lines RPMI 8226 (myeloma), CCRF-CEM (leukaemia), U937/ GTB (lymphoma) and NCI-H69 (small-cell lung cancer); the drug-resistant sublines 8226/Dox40 8226/LR5, CEM/VM-1, U937/vcr, H69AR and the primary resistant ACHN (renal adenocarcinoma). 8226/Dox40 was exposed to 0.24 μg ml⁻¹ of doxorubicin once a month, and overexpresses Pgp/MDR1/ABCBl (Dalton et al., 1986). 8226/LR5 was exposed to 1.35 μg ml⁻¹ of melphalan at each change of medium, and the resistance is proposed to be associated with increased levels of glutathione as well as genes involved in cell cycle and DNA repair (Bellamy et al., 1991; Mulcahy et al., 1994; Hazlehurst et al., 2003). U937 vcr was continuously cultured in the presence of 10 ng ml⁻¹ vincristine, and the resistance is proposed to be rubulbin associated (Bolting et al., 1994). H69AR was alternately fed with drug-free medium and medium containing 0.46 μg ml⁻¹ of doxorubicin, and overexpresses MRPI/ABCC1 (Mirski et al., 1987; Cole et al., 1992; Slovak et al., 1993). CEM/ VM-1 was cultured in drug-free medium and could be grown for 3–4 months without loss of resistance against teniposide, which is the primary resistant ACHN (renal adenocarcinoma). 8226/Dox40 was exposed to 0.24 μg ml⁻¹ of doxorubicin once a month, and overexpresses Pgp/MDR1/ABCBl (Dalton et al., 1986). 8226/LR5 was exposed to 1.35 μg ml⁻¹ of melphalan at each change of medium, and the resistance is proposed to be associated with increased levels of glutathione as well as genes involved in cell cycle and DNA repair (Bellamy et al., 1991; Mulcahy et al., 1994; Hazlehurst et al., 2003). U937 vcr was continuously cultured in the presence of 10 ng ml⁻¹ vincristine, and the resistance is proposed to be rubulbin associated (Bolting et al., 1994). H69AR was alternately fed with drug-free medium and medium containing 0.46 μg ml⁻¹ of doxorubicin, and overexpresses MRPI/ABCC1 (Mirski et al., 1987; Cole et al., 1992; Slovak et al., 1993). CEM/ VM-1 was cultured in drug-free medium and could be grown for 3–4 months without loss of resistance against teniposide, which is the primary resistant ACHN (renal adenocarcinoma).

Measurement of drug activity
A total of 66 anticancer drugs (Table 1), obtained from commercial sources or from NCI, were dissolved according to the manufacturer’s instructions and tested in five concentrations, obtained by 10-fold serial dilution. The investigational alkylating agents J1 and P2 were kind gifts from Oncopeptides AB (Stockholm, Sweden). The Fluorometric Microculture Cytotoxicity Assay (FMCA), described in detail previously (Larsson et al., 1990), is based on measurement of fluorescence generated from hydrolysis of fluoroscein diacetate (FDA) to fluoroscein by cells with intact plasma membranes. Briefly, cells were seeded into microtitre plates (Nunc, Roskilde, Denmark) prepared with drugs and incubated at 37°C and 5% CO₂ for 72 h. Then the plates were washed, FDA added, and, after 40 min of incubation, the fluorescence was measured in a Fluoroscan II (Labsystems Oy, Helsinki, Finland). The fluorescence is proportional to the number of living cells and data are presented as survival index, defined as the fluorescence of experimental wells in percent of control wells with blank values subtracted. The IC₅₀ value for each drug in each cell line was obtained from concentration–response curves constructed in Excel (Microsoft) and GraphPadPrism (GraphPad Software Inc., CA, USA).

Table 1  Anticancer drugs used in the study

| Antimetabolites |
|-----------------|
| Acivicin, Aminopterin, Aphidicolin, 5-Azacytidine, 6-Alanosine , Cldrine, Cycloxytidine, Cytarabine, 3-Dezaunauridine, 2-Azacytidine, Diglycolaldehyde, Fludarabine, 5-Fluorouracil, Ptorafl, Hydroxyurea, 6-Mercaptopurine Methotrexate, PALA, Pentostatin, 6-Thioctanine, Thymidine |

| Alkylating agents |
|-------------------|
| Busulfan, Carboplatin, Chlorambucil, Cisplatin, 4-HC, J1, Mechloretamine, Melphan, Mitomycin C, P2, Sarcolysine |

| Topoisomerase I-inhibitors |
|---------------------------|
| Camptothecin, SN-38, Topotecan |

| Topoisomerase II-inhibitors |
|----------------------------|
| Amscarine, Bisanterene, Daunorubicin, Doxorubicin, Epirubicin, Etoposide, Idarubicin, Mitoxantrone Teniposide |

| Proteosome inhibitors |
|-----------------------|
| Bortezomib, Lactacystin, MG-I 132, MG-262 |

| Tubulin active agents |
|-----------------------|
| Colchicine, Docetaxel, Maytansine, Paclitaxel, Podophyllotoxin, Vinblastine, Vincristine, Vinoreline, Vinorelbine, Eastrumstine |

| Others |
|--------|
| Aclarubicin, Angudine, Cycloheximide, Flavonacetate, Hecloet 33342, MBGB, MBG, Sipringermanium |

PALA = N-phosphonacetyl-L-aspartate; 4-HC = 4-hydroperoxy-cyclophosphamide; MGB = methylglyoxal-bis(guanylhydrazone); MIBG = meta-iiodobenzylguanidine; SN-38 = active metabolite of camptothecin; J1 and P2, oligopeptide derivatives of melphan and sarcolysine, respectively.

RNA extraction and reference composition
Total RNA was extracted from each cell line starting from 10 cells, using Trizol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s protocol. The purity of the RNA was ensured by measuring the optical density at 260 and 280 nm. The integrity of the RNA was controlled by capillary electrophoresis using a Bioanalyzer 2100 (Agilent Technologies, Palo Alto, CA, USA). Pure RNA (OD 260/280 > 1.8) without any sign of degradation was used in the subsequent experiments. The common reference RNA used in the array experiments was composed of equal aliquots from the cell lines HELA, ACHN, U937/GTb, HTERT-RPE and H69AR.

Array fabrication
In all, 7458 cDNA clones, included in the Human Sequence Verified Set, were obtained from Research Genetics (Huntsville, AL, USA). A complete list of genes printed on the arrays is available at: http://www.genpat.uu.se/Forskargrupper/wcn/UU/InstrAndProd_section.htm#prod. Plasmids containing clones were grown in Escherichia coli overnight in 96-well microtitre plates. Plasmid DNA was isolated using the Millipore Plasmid Miniprep Kit (Millipore, Bedford, MA, USA) and clone inserts were amplified using vector-specific primers (Universal Forward 5'-GTGAGCGGATAACAATTTCACACAGGAAACAGC-3’ and Universal Reverse 5’-GTCAGGGTAAACATTGCTTACACGAGAAGACGC-3’). The PCR products were purified with the Millipore Multiscreen PCR 96-well plate filtration system (Millipore) and dissolved in 45 μl MilliQ-water. The PCR products were dried and re-suspended in MilliQ-water, containing 30% DMSO, to a final concentration of 0.1 mg ml⁻¹. The PCR products were printed with a Cartesian Prosys 5510A (Cartesian Technologies Inc., Irvine, CA, USA) in duplicates with eight 3B Stealthpins (TeleChem International Inc., Sunnyvale, CA, USA) on GAPSII slides (Corning Life Sciences, Sunnyvale, CA, USA).
Molecular mechanisms for drug resistance
L Richardson et al

RESULTS

Analysis of the gene expression and drug activity data sets

A cDNA microarray analysis was performed to investigate the expression profiles of the 7458 genes in each of the 10 cell lines. Of these genes, 3903 fulfilled the preset quality criteria for subsequent analyses. An example is shown in Figure 1, in which the accurate detection of the ABCB1 transporter in the cell lines is shown. In general, cDNA microarray expression data need to be validated to ensure that the correct gene expression has been measured. In this case, oligonucleotide arrays with a shorter more specific probe has been used to validate MRPl/ABCC1 expression (correlation coefficient r > 0.9, data not shown). H69AR showed an increased expression of MRPl/ABCC1 compared to all other cell lines, which is consistent with previous results, further supporting the validity of the array measurements (Cole et al, 1992). A hierarchical clustering method was then applied to the gene expression in the cell lines (Figure 2). The parental cell lines clustered with their resistant sublines, indicating that no gross alteration in the gene expression profile resulted from the selection of the drug-resistant sublines. Next, correlations were established between the log 2 expression values of each of these 3903 genes and the log 10 IC50 values obtained for each of the 66 drugs included in the study. Hierarchical clustering of drugs based on these drug–gene correlations resulted in clusters consisting of drugs with similar modes of action (Figure 3). All proteasome inhibitors and topoisomerase I (Topi) inhibitors and most of the antitubulins, topoisomerase II (Top2) inhibitors and alkylating agents formed distinct clusters. Notable exceptions were the tubulin active agents vindesine and estramustine, which did not cluster within their assigned mechanistic group. The antimetabolites clustered more heterogeneously, but closely related drugs with respect to mechanism of action, such as the dihydrofolate reductase inhibitors methotrexate and aminopterin, clustered together. Also, J1 and P2, oligopeptide derivatives of melphalan and sarcosynes, respectively, did not cluster with their parent compounds. Clustering of drugs based on drug activity alone yielded similar results as the clustering based on the drug–gene correlations (data not shown). An example of a typical drug–gene relationship is shown in Figure 4 Concentration–response curves for doxorubicin extracted from more than 500000 Medline abstracts and full-length articles (ResNet update Q4 2004).

Identification of molecular pathways

The genes connected to general chemo-sensitivity and resistance were analysed using PathwayAssist software to identify signalling pathways (Pathway assist v3.0. (www.ariadnegenomics.com). PathwayAssist is a software for visualisation and exploration of biological pathways, gene regulation networks and protein–protein interactions. PathwayAssist is supplied with ResNet molecular interaction and pathway database, which contains more than 500000 functional links for more than 50000 proteins,
Figure 2  Two-dimensional hierarchical clustering analysis based on similarities in gene expression in the cell lines.

Figure 3  Two-dimensional hierarchical clustering analysis based on drug–gene correlations (Pearson’s correlation coefficients) for drug response data (log_{10} IC_{50}) of 66 anticancer drugs and 3903 genes (log 2) in the 10 cell lines.
expression of STAT1 (log 2) in the cell lines were highly correlated (panel D, \( R = 0.89 \)). Table 2 displays the 40 genes with the highest positive and negative correlations to doxorubicin.

### Identification of signalling pathways associated to drug sensitivity and resistance

Genes where \( R > 0.70 \) and \( < -0.70 \) were extracted for each of the 66 drugs (supplementary information online). A correlation coefficient of \( > 0.70 \) or \( < -0.70 \) in at least 20 of the 66 drugs was set as the criterion for the selection of genes associated to chemosensitivity. This selection identified 122 and 74 genes correlated to general resistance and sensitivity, respectively. Next, Pathway Assist was used in two steps to explore the interactions between the genes and, in the second step, the genes were searched for linkage to cellular processes involving cellular proliferation, cell survival, cell death or apoptosis. The genes selected in this way to form these molecular networks are listed in Tables 3 and 4. The two networks are accessible in supplementary information online as html web files, and the connections are clickable (dots on lines) to access hyperlinks to the Medline references on which the networks are based. Clicking on the nodes provides hyperlinks to several gene and protein databases, including HUGO, OMIM, Locus Link and Swiss-Prot for the particular protein. A simplified version of the network for genes associated with drug resistance is shown in Figure 5. Regarding genes associated to sensitivity, there was a considerable number that could be linked to cell cycle and proliferation regulation rather than apoptosis, including genes such as CDC25A, CCNC, CCND3 and STAT5A (Figure 5A). Notably, for the resistance associated genes, both known proapoptotic and antiapoptotic pathways were detected in the resulting network (Figure 5B). In this molecular network, caspase 3 and 6 and Jun were identified together with survival genes such as RB1, calpastatin, PTK2 and MAPK1. These gene/pathway maps may provide novel potential molecular targets for therapy. In addition to the genes selected by Pathway Assist, several other potentially relevant genes fulfilled the general resistance and sensitivity criteria including ABC transporters, drug-inactivating enzymes and protein kinases (for complete general sensitivity and resistance lists, see the supplementary information online).

### DISCUSSION

Gene–drug relationships in large panels of cancer cell lines with different histological origins have been studied previously (Scherf et al, 2000; Dan et al, 2002). In the present study, we studied the gene expression and drug activity in a panel of 10 cell lines representing different mechanisms of anticancer drug resistance. Previous studies have shown that drug activity patterns in this panel can be used to classify anticancer drugs according to mechanism of action (Dhar et al, 1996). Here we showed that this classification also corresponded to identifiable patterns of gene expression and that the genes which correlated to drug sensitivity and resistance seem to be biologically relevant. The gene-expression profiles of the cell lines were similar for cells with the same histological origin and the hierarchical clustering performed based on drug–gene correlations for the drugs in the cell lines yielded clusters of drugs based on their main mechanism of action, with some exceptions. There are several possible reasons for incorrect clustering, and these include experimental variability and incorrect or incomplete assignment of the mechanism of action. Concerning the antimetabolites, the clustering was not clearly linked to known structural or mechanistic features. Given the very diverse mechanistic properties of these drugs, this was not an unexpected finding. Other drugs that deviated from the expected...
observed to be highly correlated to resistance, particularly for the tumour cell survival. To affect this balance by small molecules may upregulated pro- and antiapoptotic genes may be critical for...

Table 2 The genes with highest positive and negative correlations to doxorubicin

| Symbol     | Acc ID      | Name                                                   | R  |
|------------|-------------|--------------------------------------------------------|----|
| CTNN       | M98343      | Cortactin                                              | 0.96|
| SLC39A1    | BC047288    | Solute carrier family 39 (zinc transporter), member I  | 0.93|
| TTP2       | NM_004254   | Hypothetical protein                                   | 0.93|
| TPI        | BM191099    | Triosephosphate isomerase                              | 0.93|
| DDAH1      | NM_012137   | Dimethylarginine dimethylaminohydrolase                | 0.92|
| EXTL1      | NM_004455   | Exostoses (multi)-like                                  | 0.92|
| GNAI1      | BC063426    | Guanine nucleotide binding protein (G protein), alpha I  | 0.92|
| MAPK11     | BC027933    | Mitogen-activated protein kinase II                     | 0.92|
| SBDG2      | NM_004264   | SRFB7 suppressor of RNA polymerase B homolog (yeast)   | 0.91|
| HLA-DOA    | NM_002119   | Major histocompatibility complex, class II, DO alpha   | 0.90|
| STAT1      | NM_007315   | Signal transducer and activator of transcription 1, 91 kDa | 0.89|
| AGRN       | AB191264    | Agranin                                               | 0.89|
| PTG1IP     | AK095586    | Pituitary tumour-transforming 1 interacting protein    | 0.89|
| FXYD1      | AK124802    | PXFYD domain containing ion transport regulator        | 0.88|
| DRPLA      | BC051795    | Dentatorubral-pallidusylian atrophy                   | 0.88|
| TULP3      | NM_003324   | Tubby like protein 3                                   | 0.88|
| BCAR1      | AK124526    | Breast cancer anti-oestrogen resistance 1              | 0.88|
| SPAG9      | AF327452    | Sperm associated antigen 9                            | 0.87|
| ABCB6      | BC043423    | ATP-binding cassette, subfamily B (MDR/TAP), member 6  | 0.87|
| CAST       | NM_173606   | Calpastatin                                            | 0.87|
| BNIP2      | AK125533    | BCL2/adenovirus E1B 19 kDa interacting protein 2       | 0.87|
| GCAT       | AK123190    | Glycine C-acetyltransferase                            | 0.87|
| TIMM10     | BQ011318    | Translocase of inner mitochondrial membrane 10 homolog (yeast) | 0.91|
| RNUT1      | BG421329    | RNA, U transporter 1                                   | 0.90|
| ASCC3      | AL834463    | D1467N11.1 protein                                    | 0.90|
| GAS7       | NM_201433   | Growth arrest-specific 7                              | 0.88|
| CORD1A     | AK122401    | Coronin, actin-binding protein, 1A                     | 0.88|
| LCP2       | NM_005565   | Lymphocyte cytosolic protein 2                         | 0.88|
| WAS        | BM455138    | Wiskott–Aldrich syndrome                               | 0.88|
| EBP        | BE283580    | Emopamil-binding protein                               | 0.88|
| PSD4       | BC073151    | Pleckstrin and Sec7 domain containing 4                | 0.87|
| KIAA1545   | AB046765    | KIAA1545 protein                                      | 0.87|
| IDH3A      | AK123316    | Isocitrate dehydrogenase 1 3 (NAD(+)-) alpha          | 0.87|
| NIPBL      | AI627032    | Nippl-B homolog (Drosophila)                           | 0.86|
| POLQ       | NM_006596   | Polymerase (DNA directed), theta                       | 0.86|
| C15orf22   | AK075529    | Chromosome 15 open reading frame 22                    | 0.85|
| RAC2       | AK096924    | Ras-related C3 botulinum toxin substrate 2            | 0.85|
| PHF2       | NM_005392   | PHD finger protein 2                                   | 0.85|
| TGBG       | NM_006670   | Trophoblast glycoprotein                              | 0.85|
| ARHGDIIB   | AK125625    | Rho GDP dissociation inhibitor (GDI) beta              | 0.84|

clustering were vindesine, estramustine, J1 and P2. As an example, J1 and P2, oligopeptide derivatives of melphalan and sarcosylife, respectively, clustered together, but differently from their parent compounds. J1 is currently undergoing clinical development, and recent studies have indicated other mechanisms of cell death additional to the death caused by DNA alkylation (Gullibo et al., 2003). The overall results indicate that the panel of 10 tumour cell lines was able to reasonably well classify drugs with respect to the mechanism of action.

The mechanistic pathways identified with PathwayAssist associated to general drug resistance paradoxically included a substantial number of both proapoptotic and antiapoptotic genes. The proapoptotic genes caspase 3 and 6 (CASP3, 6) and Jun were identified together with survival genes such as retinoblastoma 1 (RB1), calpastatin (CAST), focal adhesion kinase/protein tyrosine kinase 2 (FAK/PTK2) and mitogen-activated protein kinase 1 (MAPK1). A parallel upregulation of pro- and antiapoptotic genes in malignant tumours has been observed in several microarray studies comparing tumour cells and normal tissue (Rhodes et al., 2004; www.oncomine.com), indicating that the balance between upregulated pro- and antiapoptotic genes may be critical for tumour cell survival. To affect this balance by small molecules may thus be a potential therapeutic strategy. The expression of signal transducer and activator of transcription 1 (STAT1) was also observed to be highly correlated to resistance, particularly for the Top2 inhibitors (data not shown). Although activation of STAT1 in some cell systems has been shown to be proapoptotic (Calo et al., 2003), a recent observation has indicated a role for STAT1 in mediating radioresistance (Khodarev et al., 2004). Recently, a correlation between STAT1 expression and cisplatin resistance in cell lines derived from patients with ovarian carcinoma was also reported (Roberts et al., 2005), and inhibitors of the STAT1 pathway have been shown to induce apoptosis in leukemic cells from patients (Martinez-Lostao et al., 2005). The pathway analysis showed that STAT1 is positively influenced by MAPK1 and FAK, two of the most highly connected resistance-associated genes, both of which have been reported to inhibit apoptosis (Shimada et al., 2002; Kurenova et al., 2004). Notably, STAT1 expression has been reported higher in tumour compared with corresponding normal tissue for a wide range of tumour types (www.oncomine.com). The STAT1 pathway may thus provide a potentially interesting drug target for reversal of drug resistance.

The genes correlated to drug sensitivity had diverse functions, but a considerable number were found to be related to cell cycle and proliferation rather than to apoptosis, for example, cell division cycle 25A (CDC25A) and signal transducer of activator of transcription 5A (STAT5A). This is in accordance with the general notion of a correlation between high proliferation and increased anticancer drug sensitivity (Valeriote and van Putten, 1975; Kaaijk et al., 2003).
### Table 3: Genes associated with drug resistance selected by PathwayAssist

| Symbol  | Name                                      |
|---------|-------------------------------------------|
| AGRN    | Agrin                                     |
| APP     | Amyloid beta (A4) precursor protein (protease nexin-II, Alzheimer’s disease) |
| BACE2   | Beta-site APP-cleaving enzyme 2           |
| BAG3    | Bcl2-associated athanogene 3              |
| BASP1   | Brain abundant, membrane-attached signal protein 1 |
| BCAR1   | Breast cancer antiestrogen resistance 1    |
| BMP1RA  | Bone morphogenetic protein receptor, type IA |
| CASP3   | Caspase 3, apoptosis-related cysteine protease |
| CASP6   | Caspase 6, apoptosis-related cysteine protease |
| CAST    | Calpastatin                               |
| CD9     | CD9 antigen (p24)                         |
| CKAP4   | Cytoskeleton-associated protein 4          |
| CREEBBP | Cytoskeletal protein                      |
| CSPC2   | Chondroitin sulphate proteoglycan 2 (versican) |
| CTNN    | Cortactin                                 |
| DAG1    | Dystroglycan 1 (dystrophin-associated glycoprotein 1) |
| DDAH1   | Dimethylarginine dimethylamino-hydrolase 1 |
| DRPLA   | Dentatorubral-pallidolusian atrophy (atrophi-n-1) |
| EPHA2   | EphA2                                     |
| FXRD1   | FXYD domain containing ion transport regulator 1 (phospholemman) |
| HIF1A   | Hypoxia-inducible factor 1, alpha subunit (basic helix–loop–helix transcription factor) |
| IGSF4   | Immunoglobulin superfamily, member 4      |
| ITGA7   | Integrin, alpha V (vitractorin receptor, alpha polypeptide, antigen CD51) |
| ITIPR3  | Inositol 1,4,5-trisphosphate receptor, type 3 |
| ITSN1   | Intersectin 1 (SH3 domain protein)        |
| JUN     | Jun oncogene                              |
| LTPB1   | Latent transforming growth factor beta binding protein 1 |
| MAPK    | V-maf musculoaponeurotic fibrosarcoma oncogene homologue G (avian) |
| MAPK3   | Mitogen-activated protein kinase kinase kinase 3 |
| MAPK1   | Mitogen activated protein kinase 1         |
| MAPK11  | Mitogen-activated protein kinase 11        |
| MDK     | Midkine (neurite growth-promoting factor 2) |
| NBL1    | Neuroblastoma, suppression of tumorigenicity 1 |
| NEFL    | Neurofilament, light polypeptide 47 (collagen-binding protein 1) |
| PARN    | PRK, apoptosis, WTI, regulator            |
| PEA15   | Phosphoprotein enriched in astrocytes 15   |
| PLXNB1  | Plexin B1                                 |
| POR     | P450 (cytochrome) oxidoreductase          |
| PTK2    | PTK2 protein tyrosine kinase 2            |
| PTEN    | Protein tyrosine phosphatase, nonreceptor type 13 |
| PXN     | Paxillin                                  |
| R1B1    | Retinoblastoma 1                          |
| RDX     | Radixin                                   |
| RRP2    | Receptor-interacting serine–threonine kinase 2 |
| S100A10 | S100 calcium-binding protein A10 (annexin II ligand, calpentin, light polypeptide, (p.11)) |
| SERPINH1| Serine (or cysteine) proteinase inhibitor, clade D (heat shock protein 47), member 1 (collagen-binding protein 1) |
| STAT1   | Signal transducer and activator of transcription 1 |
| TPI     | Triosephosphate isomerase 1               |
| TRA1    | Tumour rejection antigen (gp96) 1         |
| TUBB    | Tubulin, beta polypeptide                 |
| TULP1   | Tubby-like protein 2                      |

The listed genes were selected by the PathwayAssist software as described in the Results section. An interactive graphical version is available in the supplementary information online.

Some limitations of the study should be discussed. First, cell lines removed from their in vivo environment and selected for growth in culture differ from tumour cells in patients. Therefore, the relevance of the genes and mechanistic pathways needs to be studied in additional settings, such as primary cultures of tumour cells from patients. Second, the drug activity database was generated using a single assay end point, that is, short-term growth inhibition and cytotoxicity. Drugs may induce concentration-dependent effects on different targets leading to different modes of cell death, including apoptosis, necrosis and cell senescence (Blagosklonny, 2004). Multiparameter assays using high-content screening may provide a substantial increase in the information on drug activity and mode of cell death (Lövborg et al., 2004), and such studies are underway. Third, only a part of all human genes were represented on the arrays used. Also, the gene–drug relationships described represent only a small fraction of relationships thought to be relevant to chemotherapy, and many are probably hidden by the arbitrary and rough cutoff criteria that need to be applied for selection of the information, among all the available microarray data, considered to be relevant. Fourth, with respect to the data exploration, the quality of the data obtained is dependent on the information and algorithms in the software used, meaning that these data should only be used for generation of hypotheses that need further and direct confirmation. Finally, although this exploitation of array data using powerful software can provide a basis for identification of new drug targets, it should be emphasised that the relationships observed are correlative, not

### Table 4: Genes associated with drug sensitivity selected by PathwayAssist

| Symbol  | Name                                      |
|---------|-------------------------------------------|
| ARHGDIB | Rho GTP dissociation inhibitor (GDI) beta |
| BRCA2   | BRCA and CDKN1A interacting protein       |
| CCNC    | Cyclin C                                  |
| CCND3   | Cyclin D                                  |
| CD37    | CD37 antigen                              |
| CD4     | CD4 antigen                               |
| CDX2    | Caudal type homeobox box transcription factor 2 |
| CKLF    | Chemokine-like factor                     |
| CORO1A  | Coronin, actin-binding protein, 1A        |
| DCK2    | Dedicator of cytokinesis 2                |
| GAST    | Growth arrest-specific 7                  |
| GNA15   | Guanine nucleotide-binding protein (G protein), alpha 15 (Gq class) |
| HDAC1   | Histone deacetylase 1                    |
| IDH3A   | Isocitrate dehydrogenase 3 (NAD+) alpha   |
| IL2RG   | Interleukin 2 receptor, gamma (severe combined immunodeficiency) |
| IMPDH2  | IMP (inosine monophosphate) dehydrogenase 2 |
| INPP5D  | Inositol polyphosphate-5-phosphatase D    |
| LCP1    | Lymphocyte cytosolic protein 1 (L-plastin) |
| LCP2    | Lymphocyte cytosolic protein 2 (SH2 domain containing leukocyte protein of 76 kDa) |
| MAP4K1  | Mitogen-activated protein kinase kinase kinase 1 |
| MCM5    | MCM5 minichromosome maintenance deficient 5, cell division cycle 46 (S. cerevisiae) |
| MYB     | V-myc myeloblastosis viral oncogene homologue (avian) |
| MYCBP2  | MYC binding protein 2                     |
| NCF4    | Neutrophil cytosolic factor 4, 40kDa      |
| NUDC    | Nuclear distribution gene C homolog (A. nidulans) |
| PENK    | Proenkephalin                            |
| PPIH    | Peptideyl prolyl isomerase H (cyclophilin H) |
| RAC2    | Ras-related C3 botulinum toxin substrate 2 (rho family, small GTP-binding protein Rac2) |
| SLC25A5 | Solute carrier family 25 (mitochondrial carrier; adenosine nucleotide transporter), member 5 |
| SLC7A5  | Solute carrier family 7 (caticionic amino-acid transporter, y+ system), member 5 |
| STAT5A  | Signal transducer and activator of transcription 5A |
| TFR2    | Transferin receptor 2                     |
| TPGB    | Trophoblast glycoprotein                  |
| WAS     | Wiskott–Aldrich syndrome (eczema-thrombocytopenia) |

The listed genes were selected by the PathwayAssist software as described in the Results section. An interactive graphical version is available in the supplementary information online.
causal, and that these correlations must be further experimentally tested and validated.

In comparison to previous similar studies (Scherf et al, 2000; Dan et al, 2002), we identified other chemosensitivity genes. This might be explained by several limiting factors as discussed above, and include differences in cell types, arrays, drugs and assays used. Even when different arrays were used to study the same samples, the gene–drug relationships were shown to differ (Scherf et al, 2000; Staunton et al, 2001). Furthermore, in the present study, the correlation coefficients for the drug–gene correlations were in general higher than in the previous studies. This might partly be explained by the inclusion of cell lines selected for drug resistance. The selection of drug resistance may impose a larger range of gene expression across samples, leading to higher drug–gene correlation coefficients. This would also potentially increase the possibility of identifying genes specifically associated with drug resistance. An advantage of using parental and drug-resistant cell lines is that the selecting agent and genes specifically involved in resistance to that particular drug could be isolated. However, it should be noted that the ability to cluster drugs based on drug–gene correlations is not limited to drug classes used for drug resistance selection. Indeed, in the present paper, both the proteasome inhibitors and Top I inhibitors could be distinguished as distinct clusters, although no resistant cell lines representative of these drug classes were included in the panel. Extending the panel with sublines resistant to mechanistically different drugs may nevertheless improve the possibility of identifying genes involved in drug resistance by further increasing the range of relevant gene expression. We are currently introducing cell lines resistant to novel target-specific drugs such as proteasome and tyrosine kinase inhibitors.

In the present study, we employed a molecular pathway analysis tool, Pathway Assist (www.ariadnegenomics.com), for the analysis of obtained drug–gene correlations. This procedure allowed quick and efficient generation of biologically meaningful and literature-validated relationships between the genes retrieved. PathwayAssist contains the ResNet database in which more than 500,000 events are recorded and any established pathway can be updated online by automated mining of Medline using a built-in Natural Language Processing algorithm (www.ariadnegenomics.com). Performing such pathway analysis manually would have been extremely time consuming and laborious. Automated data-mining tools for pathway analysis will therefore be increasingly important in light of the exploding information content on molecular pathway networks.

In conclusion, integration of gene expression and drug activity data sets for tumour cell line panels provide relationships between individual gene and drug activity profiles that makes it possible to identify drug mechanisms of action that can be traced down to gene level. By also applying powerful software for recognition of
cell signalling pathways, the current approach might accelerate the drug discovery and evaluation process and provide novel markers and drug targets for the chemotherapy of cancer. The current approach is suitable for characterisation of new drugs both with respect to the mechanism of action and identification of genes involved in drug sensitivity and resistance.

ACKNOWLEDGEMENTS

We are grateful for all the work with microarray printing performed by Niclas Olsson at the Uppsala Expression Array Platform, Uppsala, Sweden. The skilful technical assistance of Christina Leek and Lena Lenhammar is gratefully acknowledged. This study was supported by the Swedish Cancer Society, the Swedish Research Council, the Lions Cancer Research Fund, Beijer foundation. Wallenberg Consortium North, Marcus Borgström Foundation, Swedish Society for Medical Research, Göran Gustafsson Foundation, Carl Tryggers Foundation, Stockholm Cancer Society and Swedish Knowledge Foundation.

Supplementary Information accompanies the paper on British Journal of Cancer website (http://www.nature.com/bjc).

REFERENCES

Bellamy WT, Dalton WS, Gleason MC, Grogan TM, Trent JM (1991) Development and characterization of a melphalan-resistant human multiple myeloma cell line. Cancer Res 51: 995 – 1002

Blagosklonny MV (2004) Prospective strategies to enforce selectively cell death in cancer cells. Oncogene 23: 2967 – 2975

Botling J, Liminga G, Larsson R, Nygren P, Nilsson K (1994) Development of vincristine resistance and increased sensitivity to cyclosporin A and verapamil in the human U-937 lymphoma cell line without overexpression of the 170-kDa P-glycoprotein. Int J Cancer 58: 269 – 274

Boyd MK, Pauli KD (1995) Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Dev Res 34: 91 – 109

Calo V, Migliavacca M, Bazan V, Macaluso M, Buscemi M, Gabbia N, Russo A (2003) STAT proteins: from normal control of cellular events to tumorigenesis. J Cell Physiol 211: 157 – 168

Cole SP, Bhaward G, Gerlach JH, Mackie JE, Grant CE, Alquist KC, Stewart AJ, Kurz EU, Duncan AM, Deelye RG (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258: 1650 – 1654

Dalton WS, Durie BG, Alberts DS, Gerlach JH, Cress AE (1986) Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein. Cancer Res 46: 5125 – 5130

Dan S, Tsunoda T, Kitahara O, Yanagawa R, Zembutsu H, Katagiri T, Yamazaki K, Nakamura Y, Yamori T (2002) An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. Cancer Res 62: 1139 – 1147

Danks MK, Schmidt CA, Curtin MC, Suttle DP, Beck WT (1988) Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26. Cancer Res 48: 598 – 604

Danks MK, Yalovich JC, Beck WT (1987) Atypical multidrug resistance in a human leukaemic cell line selected for resistance to teniposide (VM-26). Cancer Res 47: 1297 – 1301

Dhar S, Nygren P, Csoka K, Botling J, Nilsson K, Larsson R (1996) Anti-cancer drug characterisation using a human cell line panel representing defined types of drug resistance. Br J Cancer 74: 888 – 896

Gulbó J, Dhar S, Luthman K, Ehrsson H, Lewensohn R, Nygren P, Larsson R (2003) Antitumor activity of the alkylating oligopeptides J1 (7-methylphalanyl-p-t-fluorophenylalanine ethyl ester) and P2 (p-t-propyl-m-t-sarcosylt-p-t-fluorophenylalanine ethyl ester): comparison with melphalan. Anticancer Drugs 14: 617 – 624

Hazelhurst LA, Enkemann SA, Bean CA, Argilagos RF, Painter J, Shain KH, Saporta S, Boulware D, Moschinski L, Alsiina M, Dalton WS (2003) Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model. Cancer Res 63: 7900 – 7906

Kajii P, Kaspers OJ, Van Wering ER, Broekema GJ, Loonen AH, Hahlen K, Schmiegelow K, Janka-Schaub GE, Henze G, Creutzig U, Veerman AJ (2003) Cell proliferation is related to in vitro drug resistance in childhood acute leukaemia. Br J Cancer 88: 775 – 781

Karsten SL, Van Deelvin VM, Sabati C, Gill LH, Geschwind DH (2002) An evaluation of tyramide signal amplification and archived fixed and frozen tissue in microarray gene expression analysis. Nucleic Acids Res 93: 4505 – 4510

Khodarev NN, Beckett M, Labay E, Darga T, Roizman B, Weichselbaum RR (2004) STAT1 is overexpressed in tumors selected for radioreistance and confers protection from radiation in transduced sensitive cells. Proc Natl Acad Sci USA 101: 1714 – 1719

Kurenov A, Xu LH, Yang X, Baldwin Jr AS, Craven RJ, Hansk SK, Liu ZG, Cance WG (2004) Focal adhesion kinase suppresses apoptosis by binding to the death domain of receptor-interacting protein. Mol Cell Biol 24: 4361 – 4371

Larsson R, Nygren P, Ekberg M, Slater L (1990) Chemotherapeutic drug sensitivity testing of human leukaemia cells in vitro using a semi-automated fluorometric assay. Leukemia 4: 567 – 571

Lövborg H, Nygren P, Larsson R (2004) Multiparametric evaluation of apoptosis: effects of standard cytotoxic agents and the cyano- guanidine CHS 828. Mol Cancer Ther 3: 521 – 526

Mao Y, Yu C, Hsieh TS, Nittis LJ, Liu AA, Wang H, Liu LF (1999) Mutations of human topoisomerase II alpha affecting multidrug resistance and sensitivity. Biochemistry 38: 10793 – 10800

Marie JP (2001) Drug resistance in hematologic malignancies. Curr Opin Oncol 13: 463 – 469

Martínez-Lostao L, Brioners J, Forne I, Martinez-Gallo M, Ferrer B, Sierra J, Rodrigues-Sanches J, Juarez C (2005) Role of the STAT1 pathway in apoptosis by fludarabine and JAK kinase inhibitors in B-cell chronic lymphocytic leukaemia. Leukemia Lymphoma 46: 435 – 442

Mirski SE, Gerlach JH, Cole SP (1987) Multidrug resistance in a human small cell lung cancer cell line selected in adriamycin. Cancer Res 47: 2594 – 2598

Mulcahy RT, Bailey HH, Gipp JJ (1994) Up-regulation of gamma-glutamylcysteine synthetase activity in melphalan-resistant human multiple myeloma cells expressing increased glutathione levels. Cancer Chemother Pharmacol 34: 67 – 71

Nygren P (2001) What is cancer chemotherapy? Ada Oncol 40: 166 – 174

Nygren P, Larsson R (1991) Differential in vitro sensitivity of human tumor and normal cells to chemotherapeutic agents and resistance modulators. Int J Cancer 48: 598 – 604

Paull KD, Shoemaker RH, Hodes L, Monks A, Scudiero DA, Rubinstein L, Plovman J, Boyd MR (1989) Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst 81: 1088 – 1092

Pommier Y, Sordet O, Antony S, Hayward RL, Kohn KW (2004) Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene 23: 2934 – 2949

Rhodes DR, Yu J, Shanker K, Deshpande N, Ghosh D, Barrette T, Pandey A, Chinnaiyan AM (2004) Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci USA 101: 9309 – 9314

Roberts D, Schick J, Conway S, Biade S, Laub PB, Stevenson JP, Hamilton TC, O’Dwyer PJ, Johnson SW (2005) Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells. Br J Cancer 92: 1149 – 1158

Scherf U, Ross DT, Pomeroy SL, Slocum JR, Golub TR, Lander ES, Hedenfalk I, Johansson SE, Aittoglo T, Meltzer PS, Eisen MB, Spang R, Li L, Olshen R, Collins C, Michor F, slice N, Lander E (2002) Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Proc Natl Acad Sci USA 99: 6764 – 6769

Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, Tanabe L, Kohn KW, Reinhold WC, Myers TG, Andrews DT, Scudiero DA, Eisen MB, Sausville EA, Pomeroy SL, Botstein D, Brown PO, Weinstein JN (2000) A gene expression database for the molecular pharmacology of cancer. Nat Genet 24: 236 – 244
Shimada K, Nakamura M, Ishida E, Kishi M, Yonehara S, Konishi N (2002) Contributions of mitogen-activated protein kinase and nuclear factor kappa B to N-(4-hydroxyphenyl)retinamide-induced apoptosis in prostate cancer cells. *Mol Carcinogen* 35: 127–137

Slovak ML, Ho JP, Bhardwaj G, Kurz EU, Deely RG, Cole SP (1993) Localization of a novel multidrug resistance-associated gene in the HT1080/DR4 and H69AR human tumor cell lines. *Cancer Res* 53: 3221–3225

Staunton JE, Slonim DK, Coller HA, Tamayo P, Angelo MJ, Park J, Scherf U, Lee JK, Reinhold WC, Weinstein JN, Mesirov JP, Lander ES, Golub TR (2001) Chemosensitivity prediction by transcriptional profiling. *Proc Natl Acad Sci USA* 98: 10787–10792

Valeriote F, van Putten L (1975) Proliferation-dependent cytotoxicity of anticancer agents: a review. *Cancer Res* 35: 2619–2630

Weinstein JN, Kohn KW, Grever MR, Viswanadhan VN, Rubinstein LV, Monks AP, Scudiero DA, Welch L, Koutsoukos AD, Chiausa AJ, Paull KD (1992) Neural computing in cancer drug development: predicting mechanism of action. *Science* 258: 447–451

Weinstein JN, Myers TG, O’Connor PM, Friend SH, Fornace Jr AJ, Kohn KW, Fojo T, Bates SE, Rubinstein LV, Anderson NL, Buolamwini JK, van Osdol WW, Monks AP, Scudiero DA, Sausville EA, Zaharevitz DW, Bunow B, Viswanadhan VN, Johnson GS, Wittes RE, Paull KD (1997) An information-intensive approach to the molecular pharmacology of cancer. *Science* 275: 343–349

Yang YH, Dudoit S, Luu P, Lin DM, Peng V, Ngai J, Speed TP (2002) Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. *Nucleic Acids Res* 30: e15